uniQure N.V. (QURE) stock
QURENasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30224% above fair value
$20.78−1.10 (-5.03%)
Close on Nov 17, 2026Market cap $1.44BP/E –Yield –
uniQure EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
uniQure's EPS for the twelve months ending Jun 30, 2026 was -$4.04. For fiscal 2025 it was -$3.46. The highest annual figure on record is $7.04 in fiscal 2021.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$3.46 | – |
| FY2024 | Dec 31, 2024 | -$4.92 | – |
| FY2023 | Dec 31, 2023 | -$6.47 | – |
| FY2022 | Dec 31, 2022 | -$2.71 | -138.5% |
| FY2021 | Dec 31, 2021 | $7.04 | – |
| FY2020 | Dec 31, 2020 | -$2.81 | – |
| FY2019 | Dec 31, 2019 | -$3.11 | – |
| FY2018 | Dec 31, 2018 | -$2340.00 | – |
| FY2017 | Dec 31, 2017 | -$2940.00 | – |
| FY2016 | Dec 31, 2016 | -$2.93 | – |
| FY2015 | Dec 31, 2015 | -$3.72 | – |
| FY2014 | Dec 31, 2014 | -$2.91 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$1.22 | – |
| Q1 FY2026 | Mar 31, 2026 | -$0.85 | – |
| Q4 FY2025 | Dec 31, 2025 | -$0.59 | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.38 | – |
| Q2 FY2025 | Jun 30, 2025 | -$0.69 | – |
| Q1 FY2025 | Mar 31, 2025 | -$0.82 | – |
| Q4 FY2024 | Dec 31, 2024 | -$1.50 | – |
| Q3 FY2024 | Sep 30, 2024 | -$0.91 | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.16 | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.36 | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.53 | -1120.0% |
| Q3 FY2023 | Sep 30, 2023 | -$1.88 | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.44 | – |
| Q1 FY2023 | Mar 31, 2023 | -$1.63 | – |
| Q4 FY2022 | Dec 31, 2022 | $0.15 | -11.8% |
| Q3 FY2022 | Sep 30, 2022 | -$1.02 | – |
| Q2 FY2022 | Jun 30, 2022 | -$0.84 | -109.9% |
| Q1 FY2022 | Mar 31, 2022 | -$1.00 | – |
| Q4 FY2021 | Dec 31, 2021 | $0.17 | – |
| Q3 FY2021 | Sep 30, 2021 | -$0.79 | – |
| Q2 FY2021 | Jun 30, 2021 | $8.51 | – |
| Q1 FY2021 | Mar 31, 2021 | -$0.91 | – |
| Q4 FY2020 | Dec 31, 2020 | -$0.02 | – |
| Q3 FY2020 | Sep 30, 2020 | -$1.21 | – |
| Q2 FY2020 | Jun 30, 2020 | -$0.96 | – |
| Q1 FY2020 | Mar 31, 2020 | -$0.63 | – |
| Q4 FY2019 | Dec 31, 2019 | -$0.95 | – |
| Q3 FY2019 | Sep 30, 2019 | -$0.58 | – |
| Q2 FY2019 | Jun 30, 2019 | -$0.83 | – |
| Q1 FY2019 | Mar 31, 2019 | -$0.74 | – |
| Q3 FY2018 | Sep 30, 2018 | -$0.59 | – |
| Q2 FY2018 | Jun 30, 2018 | -$570.00 | – |
| Q1 FY2018 | Mar 31, 2018 | -$590.00 | – |
| Q3 FY2017 | Sep 30, 2017 | -$0.40 | – |
| Q2 FY2017 | Jun 30, 2017 | -$0.83 | – |
| Q1 FY2017 | Mar 31, 2017 | -$0.80 | – |
| Q4 FY2016 | Dec 31, 2016 | -$0.58 | – |
| Q3 FY2016 | Sep 30, 2016 | -$0.61 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?